article thumbnail

Using analytics and bioassays to de-risk your mRNA LNP drug development programme

Pharmaceutical Technology

“At the small scale, manufacturing between 1 ml and 10 ml is typically not problematic , but it’s not straightforward to replicate processes and technologies once you want to produce tens of litres of formulations,” says Dr Crowe, who manages a team that develop novel analytical assays related to LNPs and nanomaterials for drug delivery.

Bioassay 130
article thumbnail

RNA-based immunotherapy eradicates melanoma tumours

Drug Discovery World

This is because tumours have a tendency to evolve in different ways to switch off each stage of the cancer-immunity cycle,” said Yizhou Dong, corresponding author of the study, Professor of Oncological Sciences, and a member of the Icahn Genomics Institute and the Marc and Jennifer Lipschultz Precision Immunology Institute at Icahn Mount Sinai.

RNA 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Evaluating methods targeting Protein-Protein Interactions

pharmaphorum

Understanding the mechanism of PPIs and developing methods to target aberrant ones has been a key strategy in drug development. In comparison with the classic, small molecule drug discovery approach, the modulation of PPIs is more challenging. This innovative method now brings technology closer to developing genome-wide PPI networks.

Protein 125
article thumbnail

Can artificial intelligence help craft new medicines?

Drug Discovery World

Professor Sonika Bhatnagar explores how artificial intelligence is enabling drug discovery at rates never seen before. Here started the story of drug discovery. The magic bullet was the drug, while the specific mark it would reach in the syphilis causing bacteria to eliminate the disease was the drug target.

article thumbnail

Reimagining cell engineering with picodroplet microfluidic technology

Drug Discovery World

However, standard technologies used to ensure the highest value cells are progressed require multistep operations and instruments, extensive hands-on time, and lengthy liquid handling processes, as well as complex, low throughput bioassays for functional validation and verification.